UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 15, 2019

 


 

REPLIMUNE GROUP, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

001-38596

 

82-2082553

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification Number)

 

18 Commerce Way

Woburn, MA 01801

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (781) 222-9600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

REPL

 

The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 


 

Item 8.01                                           Other Events.

 

On October 15, 2019, Replimune Group, Inc. (the “Company”) issued a news release providing an update on its RP1 clinical development program in cutaneous squamous cell carcinoma and posted a related slide presentation on the Company’s website at www.ir.replimune.com. Copies of the news release and the presentation slides are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein. The Company undertakes no obligation to update, supplement or amend the materials attached hereto.

 

Item 9.01                                           Financial Statements and Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

News Release dated October 15, 2019

99.2

 

Company Presentation dated October 2019

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

REPLIMUNE GROUP, INC.

 

 

 

Date: October 15, 2019

By:

/s/ Robert Coffin

 

 

Robert Coffin

 

 

President and Chief Executive Officer

 

3


Replimune (NASDAQ:REPL)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Replimune Charts.
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Replimune Charts.